BioNTech (BNTX) Company Report

Analyst Coverage

Research analysts who have asked questions during BioNTech earnings calls.

Daina Graybosch

Leerink Partners

6 questions for BNTX

Also covers: AFMD, CGEN, FATE +6 more

Tazeen Ahmad

Bank of America

6 questions for BNTX

Also covers: ACAD, ALNY, APLS +21 more

Terence Flynn

Morgan Stanley

6 questions for BNTX

Also covers: ABBV, AMGN, ARVN +17 more

Yaron Werber

TD Cowen

6 questions for BNTX

Also covers: ALEC, AMGN, ARGX +14 more

Cory Kasimov

Evercore ISI

4 questions for BNTX

Also covers: BBIO, BMRN, CYTK +5 more

Jessica Fye

JPMorgan Chase & Co.

4 questions for BNTX

Also covers: ALKS, ALNY, AMRN +23 more

Mohit Bansal

Wells Fargo & Company

4 questions for BNTX

Also covers: ABBV, AMGN, BMRN +16 more

Akash Tewari

Jefferies

3 questions for BNTX

Also covers: ALKS, APLS, ARGX +15 more

Jay Olson

Oppenheimer & Co. Inc.

3 questions for BNTX

Also covers: ACAD, AMGN, BIIB +22 more

Asthika Goonewardene

Truist Securities

2 questions for BNTX

Also covers: ALLO, AUTL, CGEN +9 more

Harry Gillis

Berenberg

2 questions for BNTX

Also covers: QGEN

Malcolm Hoffman

BMO Capital Markets

2 questions for BNTX

Also covers: ABCL, ACAD, SDGR +1 more

Manoj Eradath

Jefferies LLC

2 questions for BNTX

Also covers: ZYME

Nic Jennings

Goldman Sachs

2 questions for BNTX

Asad Haider

Goldman Sachs

1 question for BNTX

Also covers: ABBV, BMY, JNJ +4 more

Chris Shibutani

Goldman Sachs Group, Inc.

1 question for BNTX

Also covers: ABBV, ALKS, BMY +11 more

Eliana Merle

UBS

1 question for BNTX

Also covers: ALNY, APLS, ARVN +17 more

Evan Seigerman

BMO Capital Markets

1 question for BNTX

Also covers: ABBV, AMGN, ARVN +15 more

John Newman

Canaccord Genuity Group Inc.

1 question for BNTX

Also covers: ALLO, ATRA, DCTH +4 more

Joshua Chazaro

Evercore ISI

1 question for BNTX

Joshua Tassaro

Evercore ISI

1 question for BNTX

Manos Mastorakis

Deutsche Bank

1 question for BNTX

Also covers: ARGX, GLPG

Nishan Sarna

Citigroup

1 question for BNTX

Simon Baker

Redburn Atlantic

1 question for BNTX

Also covers: AUTL, AZN, GILD +5 more

Suzanne van Voorthuizen

Kempen & Co

1 question for BNTX

Also covers: ARGX, GMAB, HOOK +3 more

Yifeng Liu

HSBC

1 question for BNTX

Also covers: GMAB

Latest news

Recent press releases and 8-K filings for BNTX.

BioNTech Forms Major Partnership for Bispecific Antibody BNT327

BNTX

New Projects/Investments

M&A

The U.S. bispecific antibodies market is projected to grow from an estimated $11.78 billion in 2024 to $271.95 billion by 2033, at a 40.1% Compound Annual Growth Rate (CAGR) from 2025 to 2033.
This market expansion is driven by the rising burden of cancer and autoimmune diseases, demand for precise therapies, FDA approvals, and increased investment in research and development.
In June 2025, BioNTech partnered with Bristol Myers Squibb in a deal valued at up to $11.1 billion for the co-development and co-commercialization of its investigational bispecific antibody BNT327. This deal includes $1.5 billion upfront, $2 billion in guaranteed payments, and up to $7.6 billion in additional development, regulatory, and commercial milestones.

Jan 21, 2026, 9:52 AM

Press Release

BioNTech Provides Strategic Business Update and 2026 Focus Areas

BNTX

Guidance Update

New Projects/Investments

M&A

BioNTech reported a preliminary, unaudited cash balance of €17.2 billion as of December 31, 2025, and increased its 2025 revenue guidance on November 3, 2025, to €2,600 - €2,800 million.
For 2026, the company anticipates a modest decline in Comirnaty revenues compared to 2025 and does not expect to recognize revenues from oncology product sales.
BioNTech has 25 ongoing Phase 2 & 3 oncology trials and expects a catalyst-rich 2026 with multiple late-stage trial readouts, Phase 3 trial initiations, and a Biologics License Application (BLA) submission for Trastuzumab pamirtecan.
The company aims to build a multi-product oncology company by 2030, targeting 17+ late-stage / pivotal trial readouts through 2030+ to become a diversified, multi-product global immunotherapy powerhouse.

Jan 13, 2026, 11:18 PM

6-K

BioNTech Reports Strong 2025 Performance and Oncology Pipeline Momentum

BNTX

Guidance Update

New Projects/Investments

M&A

BioNTech reported a strong financial position with €17.2 billion in cash, cash equivalents, and securities as of December 31, 2025.
The company increased its 2025 revenue guidance on November 3, 2025, to a range of €2,600 - €2,800 million.
BioNTech has a robust oncology pipeline with over 25 Phase 2 & 3 oncology trials ongoing in 2025 and 15 Phase 2 & 3 readouts expected in 2026-2027.
While maintaining COVID-19 vaccine market leadership with over 50% share in fall 2025, the company anticipates a modest decline in Comirnaty revenues in 2026.

Jan 13, 2026, 10:15 PM

Presentation

BioNTech Provides Business Update and Pipeline Outlook at J.P. Morgan Healthcare Conference

BNTX

Guidance Update

New Projects/Investments

M&A

BioNTech reported a strong financial position at the end of 2025 with over $17 billion in cash and cash equivalents and securities.
The company has significantly advanced its oncology pipeline, with 25 Phase 2 and 3 clinical trials ongoing and 16 clinical programs.
BioNTech anticipates a busy 2026, expecting 15 Phase 3 readouts in 2026 and 2027, including five late-stage readouts and over 15 total data readouts in 2026.
Key oncology assets like Prometimic (with eight pivotal studies by year-end 2026), Gutysava (pivotal phase, interim efficacy data expected in 2026), and BNT324 (entering Phase 3 in prostate cancer) are progressing.
The company's strategy for its large cash balance prioritizes organic growth of its internal pipeline and potential inorganic acquisitions or collaborations.

Jan 13, 2026, 10:15 PM

Transcript

BioNTech Outlines 2026 Objectives and Oncology Pipeline Strategy

BNTX

Guidance Update

New Projects/Investments

M&A

BioNTech reported a strong 2025, maintaining COVID market leadership, advancing its oncology pipeline with 25 Phase II and III clinical trials, and ending the year with over $17 billion in cash and cash equivalents and securities.
For 2026, the company's key objectives include accelerating late-stage development of its first wave of oncology assets and shifting to a tumor-centric clinical development approach.
BioNTech anticipates 15+ data readouts in 2026, including five late-stage readouts for key assets such as Prometimic, Gotistobart, and an HER2 ADC.
The company's CFO stated that the primary use of its large cash balance is to develop the internal pipeline and grow organically, with inorganic acquisitions or collaborations as a secondary priority.

Jan 13, 2026, 10:15 PM

Transcript

BioNTech Provides 2025 Achievements and 2026 Oncology Outlook

BNTX

Guidance Update

New Projects/Investments

M&A

BioNTech ended 2025 with a strong financial position, including over $17 billion in cash and cash equivalents and securities, and increased its 2025 revenue guidance.
In 2025, the company maintained COVID market leadership and significantly advanced its oncology pipeline, with 25 clinical trials ongoing and strategic deals including a partnership with BMS and acquisitions of BioPhios and CureVac.
For 2026, BioNTech's key objectives are to accelerate late-stage oncology development, build momentum with multiple combination strategies, and shift to a tumor-centric clinical development approach.
BioNTech anticipates a period of sustained clinical data output from 2026 to 2029, with 15 Phase 3 readouts expected in 2026 and 2027, and five late-stage readouts planned for 2026 alone, including for gotistobart and Prometimic.
The company plans to utilize its substantial cash balance primarily for internal pipeline development and organic growth, with inorganic acquisitions and collaborations as a secondary priority.

Jan 13, 2026, 10:15 PM

Transcript

BioNTech Outlines 2026 Strategic Focus and Financial Outlook

BNTX

Guidance Update

New Projects/Investments

BioNTech anticipates 2026 to be a catalyst-rich year with seven late-stage data readouts and 15 Phase 3 clinical trials ongoing by year-end in its oncology pipeline.
The company reported a strong financial position with approximately €17.2 billion in cash, cash equivalents, and security investments as of December 31, 2025.
BioNTech expects a modest decline in Comirnaty (COVID-19 vaccine) revenues in 2026 compared to 2025, and does not anticipate recognizing revenues from oncology products in 2026.
In November 2025, BioNTech increased its 2025 revenue guidance to €2.6-2.8 billion and lowered expense guidance ranges for R&D, SG&A, and capital expenditures.

Jan 12, 2026, 11:57 AM

6-K

BioNTech Closes Acquisition of CureVac N.V.

BNTX

M&A

New Projects/Investments

Management Change

BioNTech SE announced the completion of its acquisition of CureVac N.V., with the exchange offer's subsequent offering period expiring on December 18, 2025.
A total of 86.75% of CureVac's shares were tendered in the offer, and BioNTech expects to finalize the compulsory acquisition of the remaining shares in January 2026.
This acquisition aims to enhance BioNTech's mRNA technology platform and support its oncology strategy by complementing capabilities in mRNA design, delivery, and manufacturing.
Following the acquisition, Prof. Ugur Sahin, M.D., Sierk Poetting, Ph.D., and Ramón Zapata-Gomez will form the new Management Board of CureVac SE.

Dec 18, 2025, 9:15 PM

6-K

BioNTech and Bristol Myers Squibb Present Positive Phase 2 Data for Pumitamig in Advanced Triple-Negative Breast Cancer

BNTX

New Projects/Investments

BioNTech SE and Bristol Myers Squibb Company announced encouraging interim Phase 2 data for pumitamig (BNT327/BMS986545), an investigational bispecific antibody, in locally advanced/metastatic triple-negative breast cancer (TNBC) from a global randomized trial (NCT06449222).
As of the October 1, 2025 data cut-off, among 39 efficacy-evaluable patients in Cohort 1, pumitamig plus chemotherapy achieved a confirmed objective response rate (cORR) of 61.5%, an unconfirmed objective response rate (uORR) of 71.8%, and a disease control rate (DCR) of 92.3%.
The efficacy was observed irrespective of PD-L1 expression levels, showing a 70.6% uORR in both PD-L1 high (CPS ≥10) and PD-L1 low or negative (CPS <10) subgroups, highlighting its potential for patients with limited treatment options.
The therapy demonstrated a manageable safety profile, with Grade ≥3 treatment-related adverse events reported in 42.54% (Cohort 1) and 38.2% (Cohort 2) of patients, and no pumitamig-related deaths.
These results are consistent with previous findings and support the dose selection for the pivotal Phase 3 ROSETTA BREAST-01 trial (NCT07173751).

Dec 9, 2025, 12:25 PM

6-K

BioNTech and OncoC4 Announce Positive Phase 3 Data for Gotistobart in sqNSCLC

BNTX

New Projects/Investments

BioNTech SE and OncoC4, Inc. announced positive data on December 6, 2025, from the non-pivotal dose-confirmation stage of the global randomized Phase 3 trial PRESERVE-003 for gotistobart (BNT316/ONC-392) in patients with metastatic squamous non-small cell lung cancer (sqNSCLC).
Gotistobart demonstrated a clinically meaningful overall survival (OS) benefit, reducing the risk of death by 54% (HR=0.46) compared to standard-of-care chemotherapy (docetaxel).
At a median follow-up of 14.5 months, the median OS for gotistobart had not been reached, while the docetaxel arm achieved a median OS of 10 months. The 12-month OS rate was 63.1% for gotistobart compared to 30.3% for docetaxel.
The safety profile of gotistobart was manageable, and it has received Fast Track Designation from the U.S. FDA for the treatment of patients with metastatic NSCLC whose disease progressed on prior anti-PD-(L)1 therapy.